Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  oncolytic virotherapy
Trial Status:  Active
Results 1-25 of 45 for your search:
Start Over
TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: HCC-120402, NCT01869088
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 3 to 75
Sponsor: Other
Protocol IDs: NDV-HUJ-HMO-CTIL, NCT01174537
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1716-12, NCT01721018
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20110264, NCT01740297
Phase I / II Study Of ColoAd1 Intraperitoneally in Ovarian Cancer Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ColoAd1-2001, NCT02028117
Phase I / II Study of ColoAd1 by Sub-acute Fractionated IV Dosing in Cancer Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ColoAd1-1001, NCT02028442
MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20110265, 2014-000185-22, NCT02263508
MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I214, NCT02285816
Trial of E10A in Head and Neck Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: TG0717E10A, NCT00634595
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VLA-007, NCT01227551
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I209, NCT01619813
Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VLA 008, NCT01636882
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I213, NCT01656538
Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: I211, NCT01708993
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20120324, NCT02014441
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2014-21, NCT02192775
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20110266, 2014-001146-13, NCT02211131
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: T14-10682, NCT02272855
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: ChengduShiEn_RMZ_001, NCT02283489
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC1365, NCI-2015-00133, P30CA015083, NCT02364713
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BOND 2 version 3.4, NCT02365818
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20120325, 2013-005552-15, NCT02366195
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0671, NCI-2009-01198, P30CA015083, MAYO-MC0671, MAYO-06-004440, NCT00390299
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Genelux - P01, NCT00794131
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 13 to 30
Sponsor: Other
Protocol IDs: 13-00471, #FD-R-0003717, NCT00931931
Start Over